Montpellier-based Sensorion said it has filed clinical trial applications in France and Canada for SENS-601, also known as GJB2-GT, an AAV-based gene therapy designed to treat hearing loss caused by mutations in the GJB2 gene. The French medicines agency ANSM has granted the program a fast-track procedure, which Sensorion said should shorten the review period compared with the standard pathway. The company is also targeting an investigational new drug submission in the U.S. and a submission in Australia by the end of 2026.

Public funding alone can’t fill the financing gap for long-term nature restoration projects that mitigate the impacts of…

The image under the microscope that led to the discovery, showing liver cells producing collagen at high levels, with droplet-like structures visible in green. [Soumya Bhattacharyya / Centre for Genomic Regulation]

每一家中国农化企业的出口规划里，拉丁美洲都是一块压轴的版图。数字是诱人的：全球最大的农业用地面积，持续扩张的大豆、玉米、咖啡种植带，对农化产品永无止境的需求。PPT上写着"战略重点区域"，但到了实操层面，不少企业已经在那里折了好几轮了，还说不清楚问题出在哪里。

研究人员开发了一种解聚策略，用于生产纳米农药。 甲氨基阿维菌素苯甲酸盐 该方法无需纳米载体和表面活性剂，而是利用乙酸水溶液，生成平均直径为7纳米的颗粒。研究表明，该方法可提高颗粒的生物活性。 巨型蓟马 e 根结线虫此外，还能更好地渗透到豇豆叶和甜椒根部。

Last month, the Andes virus outbreak on a Dutch cruise ship departing from Argentina brought a transmission context for hantavirus, that was previously unprecedented, to the forefront. The Andes virus is the only member of the hantavirus family that is capable of efficient person-to-person spread through close contact with respiratory secretions. Other hantaviruses are typically spread through contact with infected rodents, making the Andes virus a much more significant public health threat.

本文作者：邵伟，高凡非，寇飞，北京市永新智财律师事务所
在申请农药登记的过程中，为了向行政主管部门提供产品化学、药效、残留、毒理、环境影响等试验数据，申请人不可避免地需要制造、使用农药产品。如果该产品仍处于专利保护期内，农药登记申请人即可能面临专利侵权风险。

摘自：《生物技术通报》 作者：金曼1 龚奕杭2 潘文波2 罗培润1 高伟2 李平东*1 唐晓艳*2,3（1.深圳市农产品质量安全检验检测中心 2.华南师范大学生命科学学院广东省植物发育生物工程重点实验室 3.深圳市作物分子设计育种研究院）

Biotechnology company SonoThera has raised $125 million in an oversubscribed Series B financing round. The financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors ARCH Venture Partners, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson Innovation – JJDC, Medical Excellence Capital, RA Capital, and Vertex Ventures HC.